Item 8.01 Other Events
On August 27, 2021, Diversicare Healthcare Services, Inc., a Delaware
corporation (the "Company"), announced the execution of an Agreement and Plan of
Merger (as it may be amended, supplemented or otherwise modified from time to
time, the "Merger Agreement"), dated as of August 26, 2021, with DAC Acquisition
LLC, a Delaware limited liability company ("Parent"), and DVCR Acquisition
Corporation, a Delaware corporation, pursuant to which Merger Sub will merge
with and into the Company, with the Company surviving as a wholly owned
subsidiary of Parent (the "Merger").
In connection with the Merger, on October 20, 2021, the Company filed a
definitive proxy statement on Schedule 14A (the "Proxy Statement") with the U.S.
Securities and Exchange Commission (the "SEC"). The Proxy Statement relates to
the special meeting of stockholders of the Company to be held on November 18,
2021, to consider matters and transactions relating to the Merger.
Since the filing of the Proxy Statement, several purported stockholders of the
Company sent demand letters (the "Demand Letters") requesting that the Company
provide additional disclosures in a supplement to the Proxy Statement. The
Company believes that the allegations in the Demand Letter are meritless and no
additional disclosure is required in the Proxy Statement. However, in order to
avoid nuisance, cost and distraction, and to preclude any efforts to delay the
closing of the Merger, the Company hereby voluntarily amends and supplements the
Proxy Statement with the supplemental disclosures (the "Supplemental
Disclosures") set forth below in this Current Report on Form 8-K (this
"Report"). The Company and its board of directors deny any liability or
wrongdoing in connection with the Proxy Statement, and nothing in this Report
should be construed as an admission of the legal necessity or materiality under
applicable laws of any of the Supplemental Disclosures.
                  SUPPLEMENTAL DISCLOSURES TO PROXY STATEMENT
The Supplemental Disclosures should be read in conjunction with the Proxy
Statement, which should be read in its entirety and is available free of charge
on the SEC's website at http://www.sec.gov. Page number references below are to
page numbers in the Proxy Statement, and capitalized terms used but not defined
herein have the meanings set forth in the Proxy Statement. To the extent the
information in the Supplemental Disclosures differs from or conflicts with the
information contained in the Proxy Statement, the information set forth in the
Supplemental Disclosures shall be deemed to supersede the respective information
in the Proxy Statement. Underlined text shows text being added to a referenced
disclosure in the Proxy Statement.
The disclosure in the last paragraph on page 5 of the Proxy Statement under the
heading "Go-Shop; Board Recommendation Change" is hereby supplemented by adding
a new second sentence to the paragraph as follows:
Upon expiration of the go-shop period, of the 63 prospective buyers contacted by
BCA, 13 parties entered into confidentiality agreements with the Company and
were provided access to certain non-public information relating to the Company.
The confidentiality agreements included, among other things, confidentiality
provisions, non-solicitation provisions and a customary standstill on the
party's ability to acquire any of the Company's common stock, but the
confidentiality agreements did not include "don't ask, don't waive" ("DADW")
provisions.
The disclosure in the seventh paragraph on page 25 of the Proxy Statement under
the heading "Background of the Merger" is hereby supplemented by amending and
restating the paragraph as follows:
On April 30, 2021, the Company executed a confidentiality agreement with Party
A, and on May 18, 2021, the Company began providing information that Party A
requested through an online data room. The confidentiality agreement included,
among other things, confidentiality provisions, non-solicitation provisions and
a customary standstill on the party's ability to acquire any of the Company's
common stock, but the confidentiality agreement did not include DADW provisions.
The disclosure in the paragraph on page 29 of the Proxy Statement immediately
preceding the heading "Recommendation of the Board; Reasons for the Merger" is
hereby supplemented by adding a new fifth sentence to the paragraph as follows:
Following the execution of the merger agreement, and pursuant to the go-shop
provision set forth in the merger agreement, BCA, acting on behalf of the
Company, commenced the go-shop process by soliciting alternative acquisition
proposals. The go-shop period expired at 11:59 p.m. (Eastern Standard Time) on
September 30, 2021. During the go-shop period, BCA contacted 63 prospective
buyers that the Company and BCA believed could have an interest in reviewing the
opportunity and had the financial ability to pursue a potential strategic
transaction with the Company. Of the 63 prospective buyers contacted, 13 parties
entered into confidentiality agreements with the Company and were provided
access to certain non-public information relating to the Company. The
confidentiality agreements included, among other things, confidentiality
provisions, non-solicitation provisions and a customary standstill on the
party's ability to acquire any of the Company's common stock, but the
confidentiality agreements did not include DADW provisions.



--------------------------------------------------------------------------------

The disclosure under "Premia Analysis" on page 35 of the Proxy Statement is
hereby supplemented by amending the first sentence in the first paragraph as
follows:
Premia Analysis. BCA reviewed and analyzed, using publicly available
information, the acquisition premia for 138 acquisition transactions announced
from July 1, 2018 to July 31, 2021. BCA sampled transactions with targets that
were public companies based in the United States, acquirers that were based in
the United States, and where the disclosed enterprise values for the
transactions were between $25 million and $200 million.
The disclosure under "Illustrative Discounted Cash Flow Analysis" on page 36 of
the Proxy Statement is hereby supplemented by amending and restating the first
paragraph as follows:
Illustrative Discounted Cash Flow Analysis. Using the Company forecasts provided
by management for the remainder of 2021 through 2030, BCA performed an
illustrative discounted cash flow analysis on the Company by calculating the
estimated net present value of the projected unlevered free cash flow
(calculated as earnings before interest and taxes, less taxes, plus depreciation
and amortization, plus non-cash lease expense reconciliation, less professional
liability cash reconciliation, plus stock compensation expense, plus WOTC tax
credits, less settlement payments, less capital expenditures, and less the
amount of any increase or plus the amount of any decrease in net working
capital). Taking into account its experience and professional judgement, BCA
used discount rates ranging from 7.5% to 8.5%, reflecting estimates of the
Company's weighted average cost of capital (referred to as "WACC") to discount
to present value as of June 30, 2021 (i) estimates of unlevered free cash flow
for the Company for the second half of 2021 through 2030 as derived from the
Company's forecasts and (ii) a range of illustrative terminal values for the
Company from $105.2 million to $126.2 million as of 2030, which were calculated
by applying a Company perpetuity growth rate of 2.5% (approximate 10-year
compounded annual growth rate of the future unlevered free cash flows of the
Company through 2030). The terminal value calculation implied exit terminal year
multiples ranging from 6.3x to 7.6x to a terminal year estimate of EBITDA of the
Company, as derived from the Company forecasts. BCA derived the WACC range by
application of the Capital Asset Pricing Model, which requires certain
company-specific inputs, including the Company's target capital structure
weightings, the cost of long-term debt and future applicable marginal cash tax
rate and a beta for the Company, as well as certain financial metrics for the
United States financial markets generally. The number of fully diluted shares of
the Company stock used in calculating the range of equity values per share was
6.7 million, which was based on management projections.
The disclosure under "Selected Transaction Analysis" on page 36 of the Proxy
Statement is hereby supplemented by amending and restating the table as follows:
      Date Announced/              Adjusted Enterprise Value1                   Target                    Acquiror              AEV / Beds            AEV / Revenue            AEV / EBITDAR            EV / EBITDA
        Date Closed                      (in thousands)
August 2021 /TBD                             $403.0                   Diversicare                      DAC Acquisition                 52,702                     0.8x                     5.2x                   4.7x
December 2017/ July 2018                    $6,011.6                  Kindred Healthcare               Humana                              nm                     1.0x                     8.6x                   9.0x
February 2014/                              $6,660.5                  Emeritus Corporation             Brookdale                      148,216                     3.3x                    12.7x                  14.9x
July 2014                                                                                              Senior Living
February 2013/                               $ 545.8                  Assisted Living Concepts         TPG Capital                     58,361                     2.4x                    14.1x                  16.8x
July 2013
June 2012/                                  $ 1,456.0                 Sun Healthcare                   Genesis                         68,281                     0.8x                     6.6x                   3.5x
December 2012                                                                                          Healthcare
July 2007/                                  $ 6,241.9                 ManorCare Inc.                   The Carlyle                    144,110                     1.6x                    13.4x                  13.2x
December 2007                                                                                          Group
January 2007/ July 2007                     $ 1,869.0                 Genesis Healthcare               Formation                       69,986                     1.0x                     9.9x                  10.1x
                                                                                                       Capital and JER
                                                                                                       Partners





--------------------------------------------------------------------------------

1. Adjusted enterprise value is calculated as equity value less cash & cash
equivalents plus debt plus estimated operating lease liability.
The disclosure on page 44 of the Proxy Statement under the heading "New
Management Arrangements" is hereby supplemented by amending and restating the
paragraph as follows:
As of the date of the merger agreement and the date of this proxy statement,
none of the Company, Parent or the merger subsidiary has had any discussions
regarding the terms of or has entered into any employment agreements with the
Company's executive officers in connection with the merger or with any of the
Company's directors with respect to directorships following the Merger.
Following the date of this proxy statement, however, certain executive officers
of the Company may have discussions, or may enter into agreements with, Parent
or the merger subsidiary or their respective affiliates regarding employment
with, or the right to purchase or participate in the equity of, the surviving
corporation or one or more of its affiliates.
Additional Information and Where to Find It
This communication relates to the proposed Merger involving the Company and may
be deemed to be solicitation material in respect of the proposed Merger. In
connection with the proposed Merger, the Company has filed relevant materials
with the SEC, including the Proxy Statement. Promptly after filing of the Proxy
Statement with the SEC, the Company mailed the Proxy Statement and a proxy card
to each Company stockholder entitled to vote at the special meeting relating to
the proposed Merger. This communication is not a substitute for the Proxy
Statement or for any other document that the Company may file with the SEC or
send to the Company's stockholders in connection with the proposed Merger.
BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF THE COMPANY
ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS (INCLUDING ANY
AMENDMENTS OR SUPPLEMENTS THERETO) FILED WITH THE SEC CAREFULLY AND IN THEIR
ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS. The
proposed Merger will be submitted to the Company's stockholders for their
consideration. The Proxy Statement was mailed on or about October 20, 2021 to
the Company's stockholders of record as of the close of business on October 5,
2021. Investors and security holders are able to obtain free copies of the Proxy
Statement and other documents filed by the Company with the SEC through the
website maintained by the SEC at www.sec.gov. Copies of the documents filed by
the Company with the SEC will also be available free of charge on the Company's
website at www.DVCR.com or by contacting the Company at Diversicare Healthcare
Services, Inc., 1621 Galleria Boulevard, Brentwood, Tennessee 37027, Attention:
Investor Relations.
Participants in the Solicitation
The Company and its directors and certain of its executive officers and
employees may be deemed to be participants in the solicitation of proxies from
the Company's stockholders with respect to the proposed Merger under the rules
of the SEC. Information about the directors and executive officers of the
Company and their ownership of shares of the Company Common Stock is set forth
in the proxy statement for the Company's 2021 annual meeting of shareholders, as
filed with the SEC on Schedule 14A on May 13, 2021. Additional information
regarding the persons who may be deemed participants in the proxy solicitations
and a description of their direct and indirect interests in the Merger, by
security holdings or otherwise, was also included in the Proxy Statement and
other relevant materials filed or to be filed with the SEC. You may obtain free
copies of these documents as described above.
Forward Looking Statements
This communication contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. The Company generally
identifies forward-looking statements by terminology such as "may," "will,"
"should," "expects," "plans," "anticipates," "could," "intends," "target,"
"projects," "contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these terms or other similar words. These
statements are only predictions. The Company has based these forward-looking
statements largely on its then-current expectations and projections about future
events and financial trends as well as the beliefs and assumptions of
management. Forward-looking statements are subject to a number of risks and
uncertainties, many of which involve factors or circumstances that are beyond
the Company's control. The Company's actual results could differ materially from
those stated or implied in forward-looking statements due to a number of
factors, including but not limited to: (i) risks associated with the Company's
ability to obtain the stockholder approval or regulatory approval required to
consummate the proposed Merger and the timing of the closing of the proposed
Merger, including the risks that a condition to closing would not be satisfied
within the expected timeframe or at all or that the closing of the proposed
Merger will not occur; (ii) the risk that stockholder litigation in connection
with the proposed transaction may affect the timing or occurrence of the
proposed transaction or result in significant costs of defense, indemnification
and liability; (iii) the occurrence of any event, change or other circumstance
or condition that could give rise to the termination of the Merger Agreement;
(iv) unanticipated difficulties or expenditures relating to the proposed Merger,
the response of business partners and competitors to the announcement of the
proposed Merger, and/or potential difficulties in employee retention as a result
of

--------------------------------------------------------------------------------



the announcement and pendency of the proposed Merger; (v) risks related to
disruption of management's attention from the Company's ongoing business
operations due to the transaction; (vi) the response of Company stockholders to
the Merger Agreement; and (vi) those risks detailed in the Company's most recent
Annual Report on Form 10-K and subsequent reports filed with the SEC, as well as
other documents that may be filed by the Company from time to time with the SEC.
Accordingly, you should not rely upon forward-looking statements as predictions
of future events. The Company cannot assure you that the events and
circumstances reflected in the forward-looking statements will be achieved or
occur, and actual results could differ materially from those projected in the
forward-looking statements. The forward-looking statements made in this
communication relate only to events as of the date on which the statements are
made. Except as required by applicable law or regulation, the Company undertakes
no obligation to update any forward-looking statement to reflect events or
circumstances after the date on which the statement is made or to reflect the
occurrence of unanticipated events.

© Edgar Online, source Glimpses